These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 35041330)
1. MicroRNAs in Pancreatic Cancer and Chemoresistance. Pan Y; Li K; Tao X; Li N; Huang J; Liu J; Xiao GG Pancreas; 2021 Nov-Dec 01; 50(10):1334-1342. PubMed ID: 35041330 [TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer. Garajová I; Le Large TY; Frampton AE; Rolfo C; Voortman J; Giovannetti E Biomed Res Int; 2014; 2014():678401. PubMed ID: 25250326 [TBL] [Abstract][Full Text] [Related]
3. The Role of MicroRNAs in Resistance to Current Pancreatic Cancer Treatment: Translational Studies and Basic Protocols for Extraction and PCR Analysis. Garajová I; Le Large TY; Giovannetti E; Kazemier G; Biasco G; Peters GJ Methods Mol Biol; 2016; 1395():163-87. PubMed ID: 26910074 [TBL] [Abstract][Full Text] [Related]
4. The underlying mechanisms of non-coding RNAs in the chemoresistance of pancreatic cancer. Xiong G; Feng M; Yang G; Zheng S; Song X; Cao Z; You L; Zheng L; Hu Y; Zhang T; Zhao Y Cancer Lett; 2017 Jul; 397():94-102. PubMed ID: 28254409 [TBL] [Abstract][Full Text] [Related]
5. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma. Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274 [TBL] [Abstract][Full Text] [Related]
7. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. Hwang JH; Voortman J; Giovannetti E; Steinberg SM; Leon LG; Kim YT; Funel N; Park JK; Kim MA; Kang GH; Kim SW; Del Chiaro M; Peters GJ; Giaccone G PLoS One; 2010 May; 5(5):e10630. PubMed ID: 20498843 [TBL] [Abstract][Full Text] [Related]
8. Circulating microRNAs as Potential Diagnostic, Prognostic and Therapeutic Targets in Pancreatic Cancer. Ebrahimi S; Hosseini M; Ghasemi F; Shahidsales S; Maftouh M; Akbarzade H; Parizadeh SA; Hassanian SM; Avan A Curr Pharm Des; 2016; 22(42):6444-6450. PubMed ID: 27539232 [TBL] [Abstract][Full Text] [Related]
10. Involvement of epithelial to mesenchymal transition in the development of pancreatic ductal adenocarcinoma. Satoh K; Hamada S; Shimosegawa T J Gastroenterol; 2015 Feb; 50(2):140-6. PubMed ID: 25216997 [TBL] [Abstract][Full Text] [Related]
11. Opportunities for translation: targeting DNA repair pathways in pancreatic cancer. Maginn EN; de Sousa CH; Wasan HS; Stronach EA Biochim Biophys Acta; 2014 Aug; 1846(1):45-54. PubMed ID: 24727386 [TBL] [Abstract][Full Text] [Related]
12. A miR-146a-5p/TRAF6/NF-kB p65 axis regulates pancreatic cancer chemoresistance: functional validation and clinical significance. Meng Q; Liang C; Hua J; Zhang B; Liu J; Zhang Y; Wei M; Yu X; Xu J; Shi S Theranostics; 2020; 10(9):3967-3979. PubMed ID: 32226532 [No Abstract] [Full Text] [Related]
13. Long noncoding RNA TP53TG1 promotes pancreatic ductal adenocarcinoma development by acting as a molecular sponge of microRNA-96. Zhang Y; Yang H; Du Y; Liu P; Zhang J; Li Y; Shen H; Xing L; Xue X; Chen J; Zhang X Cancer Sci; 2019 Sep; 110(9):2760-2772. PubMed ID: 31325400 [TBL] [Abstract][Full Text] [Related]
14. Linc00511 acts as a competing endogenous RNA to regulate VEGFA expression through sponging hsa-miR-29b-3p in pancreatic ductal adenocarcinoma. Zhao X; Liu Y; Li Z; Zheng S; Wang Z; Li W; Bi Z; Li L; Jiang Y; Luo Y; Lin Q; Fu Z; Rufu C J Cell Mol Med; 2018 Jan; 22(1):655-667. PubMed ID: 28984028 [TBL] [Abstract][Full Text] [Related]
15. Chimeric peptide supramolecular nanoparticles for plectin-1 targeted miRNA-9 delivery in pancreatic cancer. Wu Y; Tang Y; Xie S; Zheng X; Zhang S; Mao J; Wang B; Hou Y; Hu L; Chai K; Chen W Theranostics; 2020; 10(3):1151-1165. PubMed ID: 31938057 [TBL] [Abstract][Full Text] [Related]
16. Coordinated silencing of the Sp1-mediated long noncoding RNA MEG3 by EZH2 and HDAC3 as a prognostic factor in pancreatic ductal adenocarcinoma. Han T; Zhuo M; Yuan C; Xiao X; Cui J; Qin G; Wang L; Jiao F Cancer Biol Med; 2020 Nov; 17(4):953-969. PubMed ID: 33299646 [TBL] [Abstract][Full Text] [Related]
17. RELA/NEAT1/miR-302a-3p/RELA feedback loop modulates pancreatic ductal adenocarcinoma cell proliferation and migration. Luo Z; Yi ZJ; Ou ZL; Han T; Wan T; Tang YC; Wang ZC; Huang FZ J Cell Physiol; 2019 Apr; 234(4):3583-3597. PubMed ID: 30362505 [TBL] [Abstract][Full Text] [Related]
18. Identification of candidate miRNA biomarkers for pancreatic ductal adenocarcinoma by weighted gene co-expression network analysis. Giulietti M; Occhipinti G; Principato G; Piva F Cell Oncol (Dordr); 2017 Apr; 40(2):181-192. PubMed ID: 28205147 [TBL] [Abstract][Full Text] [Related]